"text","uuid:ID","id","name","label","description","instanceType"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","d6526ed9-6b70-47ac-bdac-8d7d5d4afa8f","Objective_1","OBJ1","","Main objective","OBJECTIVE"
"To document the safety profile of the xanomeline TTS.","70d01c48-11c9-4dfe-86ac-3ba9120b33e4","Objective_2","OBJ2","","Safety","OBJECTIVE"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","1a3474ed-e868-488a-9e3e-ebc39a94540d","Objective_3","OBJ3","","Behaviour","OBJECTIVE"
